Document:

exv10w13

 

    Exhibit 10.13

 

    Form of
    Restricted Stock Unit Grant Agreement under the Long-Term
    Incentive Plan of Chevron Corporation.

 

    Restricted Stock Unit Grant Agreement dated <DATE>,
    between CHEVRON CORPORATION (“Corporation”), and
    <NAME>.

 

    The Management Compensation Committee (the
    “Committee”) has selected you to receive a special
    Restricted Stock Unit award under the Chevron Corporation
    Long-Term Incentive Plan. Capitalized terms not defined in
    this Agreement shall have the same meaning as the defined terms
    in the Chevron Corporation Long-Term Incentive Plan, as amended
    from time to time (the “Plan”). This award is
    governed by the Plan and is subject to the following special
    terms:

 

    1. You have been awarded <X,XXX>
    Restricted Stock Units on <DATE>.

 

    2. The restrictions on the Restricted Stock Units shall
    lapse and you shall be vested as follows: <VEST
    TERMS>, provided that your employment with the
    Corporation is not Terminated prior to the respective vesting
    dates.

 

    3. Vested Restricted Stock Units will be paid in cash,
    valued based on the closing price of a share of stock of the
    Corporation on the vesting date.

 

    4. Vested amounts are taxable as ordinary income and cash
    payment will be net of any required tax withholding.

 

    5. Your Restricted Stock Units shall be paid within
    30 days after the respective vesting date. In no event will
    payment be made more than two and one-half months following the
    end of the calendar year in which the Restricted Stock Unit
    award vests.

 

    6. No deferral of the payment date shall be permitted under
    this Agreement.

 

    7. The Restricted Stock Units representing this award shall
    be subject to adjustment for Recapitalization in the manner
    provided in the Plan, as it may be amended from
    time-to-time.

 

    8. Your Restricted Stock Units will earn Dividend
    Equivalents when Chevron pays a dividend on its common shares,
    in the form of additional Restricted Stock Units.

 

    9. No certificate for shares of stock shall be issued at
    the time the grant is made and you shall have no right to or
    interest in shares of stock of the Corporation as
    the result of this grant agreement.

 

    10. Prior to distribution of your Restricted Stock Units,
    if you are terminated by the Corporation for
    “Misconduct” as defined in the Plan, the
    award shall be canceled unless the Committee, in its sole
    discretion, elects not to cancel such award. In addition, with
    respect to any restricted stock units that became vested and
    paid after the date of your Misconduct: (i) any such
    payment may be forfeited and (ii) the Corporation may
    demand that you pay over to the Corporation any such payment you
    received.

 

    11. This award under this Agreement may not be transferred
    by you during your lifetime and may not be assigned, pledged or
    otherwise transferred except by the laws of descent and
    distribution.

 

    12. This Agreement shall not confer on you the right to
    continued employment by the Corporation, nor shall this award
    interfere in any way with the right of the Corporation to
    terminate your employment at any time.

 

    13. This Agreement is not subject to any provisions of the
    Employee Retirement Income Security Act (ERISA) of 1974.

 

    14. This award is subject to your signing the enclosed copy
    of this agreement and returning it in the envelope provided. By
    accepting this award, you agree to keep this agreement and all
    of its provisions confidential and not to disclose any parts
    thereof to third parties, except that information relating to
    this agreement may be divulged (i) to the extent required
    by any court order, (ii) to any public authority such as
    the IRS, (iii) in connection with any tax filing or
    (iv) to any financial advisors or tax consultants. Please
    retain the original of this Agreement with your
    important papers.

 

    Accepted:

    

    E-4exv10w16

 

    Exhibit 10.16

 

    Agreement
    between Chevron Corporation and R. Hewitt Pate

 

    February 21, 2012

 

    Mr. R. Hewitt Pate

    Vice President and General Counsel

    Chevron Corporation

    6001 Bollinger Canyon Road

    San Ramon, CA 94583

 

    Dear Hew,

 

    This letter agreement (“Agreement”) sets forth the
    agreement between you and Chevron Corporation (the
    “Company”) and shall be effective on February 21,
    2012.

 

    If your employment with the Company is terminated for any
    reason, including retirement, on or after August 1, 2019,
    you shall be subject to the termination provisions of the
    Long-Term Incentive Plan of Chevron Corporation
    (“LTIP”) as if you had 75 points (the sum of your age
    and years of service) or equivalent termination provisions if
    current LTIP provisions are modified.

 

    In the event that your employment with the Company is terminated
    by reason of death or disability, this Agreement shall inure to
    the benefit of your heirs, personal representatives, successors
    and assigns. Notwithstanding this Agreement, you will continue
    to be an at-will employee governed by the terms and conditions
    applicable to similarly situated employees of the Company. This
    Agreement shall be governed by the law of the State of
    California. This Agreement is the entire agreement between you
    and the Company and supersedes any prior agreements between you
    and the Company, whether written or oral, with respect to the
    subject matter of this Agreement.

 

    By executing this Agreement in the space provided below you
    agree to the terms and conditions specified herein.

 

    Sincerely yours,

    /s/JOE W. LAYMON

    Joe W. Laymon

 

    R. HEWITT PATE

 

    /s/  R.
    HEWITT PATE

 

    Date: February 21,
    2012          

    

    E-5exv4w30

    EXHIBIT 4.30
    

 

    CONFIDENTIAL
    TREATMENT REQUESTED
    

    [*] indicates confidential portions omitted pursuant to a
    request for confidential treatment and filed separately with the
    Securities and Exchange Commission

 

    SECOND
    AMENDMENT TO LICENSE, DISTRIBUTION, MANUFACTURING

    AND SUPPLY AGREEMENT
    

 

    This Second Amendment to License, Distribution, Manufacturing
    and Supply Agreement (this “Second Amendment”) is made
    and entered into on September 30, 2011 , with an effective
    date of November 1, 2010, except where otherwise stated, by
    and between LUITPOLD PHARMACEUTICALS, INC., a corporation duly
    organized and existing under the applicable laws of the State of
    New York, and having a principal place of business in Shirley,
    New York (hereinafter referred to as “Luitpold”),
    AMERICAN REGENT, INC., a corporation duly organized and existing
    under the applicable laws of the State of New York, and having a
    principal place of business in Shirley, New York (hereinafter
    referred to as “AR”, and Luitpold and AR collectively
    referred to as “Luitpold/AR”), and FRESENIUS USA
    MANUFACTURING, INC., a corporation duly organized and existing
    under the applicable laws of the State of Delaware, and having a
    principal place of business in Waltham, Massachusetts
    (hereinafter referred to as “FUSA”), each a
    “Party” and collectively “the Parties”.

 

    WHEREAS, the Parties hereto are parties to a LICENSE,
    DISTRIBUTION, MANUFACTURING AND SUPPLY AGREEMENT, dated
    May 30, 2008, as amended by a First Amendment entered into
    on September 13, 2008 (the “License Agreement”);
    and

 

    WHEREAS, the Parties hereto desire to amend the License
    Agreement to revise certain provisions thereof to the intent of
    the Parties;

 

    NOW THEREFORE, the Parties hereto, intending to be
    legally bound, agree as follows:

 

    1.     Section 1.01 of the License
    Agreement is amended as follows:

 

    The definition of “[ * ]” shall be replaced in its
    entirety by the following:

 

    [ * ]

 

    The definition of “[ * ]” shall be replaced in its
    entirety by the following:

 

    [ * ]

 

    2.     Section 6.11(a) of the
    License Agreement is amended and replaced as follows:

 

    [ * ]

 

    3.     Exhibit 1.01-A
    to the License Agreement, as amended, is replaced and restated
    in its entirety as of the Effective Date of November 1,
    2010 by new
    Exhibit 1.01-A-1
    and
    Exhibit 1.01-A-2
    attached to this Second Amendment, which shall be labeled
    prominently with the legend “Execution Copy,” made and
    entered into as of the date of FTC approval of this Second
    Amendment, or thirty (30) days after submission, whichever
    occurs first, and initialed by the Parties to this Amendment.
    Luitpold/AR and FUSA agree that
    Exhibit 1.01-A-1
    and
    Exhibit 1.01-A-2
    attached to this Second Amendment is the final agreement between
    the Parties.

 

    4.     Exhibit 1.01-B
    ([ * ]) to the License Agreement is amended to add the following:

 

    [ * ]

    

    -2-

 

    5.     The Parties further recognize
    and agree that certain new customers with facilities both inside
    and outside the Field may prefer the efficiencies of meeting all
    of their Product requirements from a single Party. Therefore,
    the Parties agree to negotiate in good faith to include all of
    each such customer’s facilities and patients either inside
    or outside the Field; any such discussions should include a
    discussion of any and all other relevant terms, including any [
    * ]. If the Parties cannot agree, then [ * ] in accordance with
    Sections 12.16 and 12.18 of the License Agreement.

 

    6.     Except as expressly amended by
    this Second Amendment, the License Agreement shall remain in
    full force and effect. The representations, warranties and
    covenants of the signatories contained in the Amendment are true
    and correct in all material respects as of and on the date
    hereof as if made again on the date hereof or as of the
    Effective Date (as applicable).

 

    7.     This Second Amendment may be
    executed in facsimile counterparts, each of which shall have the
    legal binding effect of an original signature, but all of which
    together shall constitute one and the same instrument.

 

    [Signatures are on the following page.]

    

    -3-

 

    IN WITNESS WHEREOF, the Parties hereto have duly executed this
    Second Amendment to License, Distribution, Manufacturing and
    Supply Agreement as of the date first set forth above.

 

    LUITPOLD PHARMACEUTICALS, INC.
    

 

			
	 	    By: 
    
	
    /s/  Mary
    Jane Helenek

    

    Name: Mary Jane Helenk
    

    Title: President &
    CEO
    

 

    AMERICAN REGENT, INC.
    

 

			
	 	    By: 
    
	
    /s/  Mary
    Jane Helenek

    

    Name: Mary Jane Helenek
    

    Title: President &
    CEO
    

 

    FRESENIUS USA MANUFACTURING, INC.
    

 

			
	 	    By: 
    
	
    /s/  Rice
    Powell

    

    Name: Rice Powell
    

    Title: CEO, FMCNA
    

    

    -4-

 

    EXHIBIT TO
    SECOND AMENDMENT TO LICENSE AGREEMENT

 

    EXHIBIT 1.01-A-1

 

    [ * ]
    

    

    -5-

 

    [ * ]
    

    

    -6-

 

    [ * ]
    

    

    -7-

 

    Exhibit 1.01-A-2

    

 

    [ * ]
    

    

    -8-

 

    [ * ]
    

    

    -9-

 

    [ * ]
    

    

    -10-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]